TG Therapeutics, Inc. (TGTX) — Fair Value Analysis

Base-case fair value (P50): $56.61 · Current price: $42.86 · Verdict: Undervalued

The Verdict on TGTX

TG THERAPEUTICS INC (TGTX) currently trades at $42.86. Our Monte Carlo simulations, modeling thousands of forward-looking scenarios, suggest a median fair value (P50) of $56.61. This represents a potential upside of +32.1% from the current trading price. Despite this projected upside, our overall verdict for TGTX is 'Fairly Valued'. This indicates that while there's room for appreciation under various outcomes, the market is largely pricing the stock appropriately given its comprehensive risk profile and the full spectrum of potential outcomes modeled.

How TGTX stacks up against peers

When evaluating TGTX against its sector peers, our analysis places its operational and financial health in the 'average' quality tier. This assessment, derived from a comparative review of key performance indicators and stability metrics, directly underpins the 'Fairly Valued' verdict. An average quality tier suggests TGTX exhibits neither significant competitive advantages nor glaring weaknesses relative to its industry counterparts. This balanced positioning helps explain why its current trading price of $42.86 is considered reasonable despite the indicated +32.1% potential upside to its median fair value of $56.61.

What this means for investors

For investors, the 'Fairly Valued' verdict on TGTX, combined with a median fair value of $56.61 representing a +32.1% potential return from its current $42.86, suggests a balanced risk-reward profile rather than a deep value opportunity. While our Monte Carlo simulations identify upside scenarios, investors should also consider the various downside scenarios that contribute to the overall fair valuation. The 'average' quality tier further reinforces that TGTX isn't a clear standout but rather a company whose current market price reflects its fundamental trajectory. To fully understand the comprehensive distribution of possible outcomes, including precise bear and bull case targets, sign up for a free FairCurve account to see the full Monte Carlo distribution and track TGTX's fair value as new fundamentals are released.